European Pharmaceutical Review

FEBRUARY 8, 2023

GlobalData predicts Bristol-Myers Squibb’s Breyanzi and Gilead’s Yescarta are set to have high annual sales in the forecast period. It is set to retain its market-leading position as the most lucrative CD19 CAR-T agent in NHL, with annual sales reaching $1.7 Peak sales are anticipated to reach $1.3 billion in 2031.

Marketing 98

Marketing Sales Physicians Patients 98

PM360

SEPTEMBER 21, 2023

Over the next few weeks, manufacturers will submit a range of clinical, marketing, sales, pricing, and patient data, and then meet with CMS to discuss submissions later this fall. After this period, CMS will begin to include physician-administered drugs covered under Part B in the program.

Manufacturing 111

Manufacturing Marketing Competition Physicians 111

Evolve Your Success

OCTOBER 31, 2023

He provides a fascinating glimpse into what it takes to excel in the field of medical device sales, emphasizing the importance of authenticity and passion. The perfect blend of persistent dedication, a heartwarming touch of southern hospitality, and an innate understanding of the needs of both physicians and patients.

Engineering 52

Engineering Sales Medical sales Medical 52

Clarivate

OCTOBER 25, 2023

The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Legacy MEDSearch

MAY 23, 2022

BN by 2027. He is a former assistant team physician to The Cleveland Guardians and Cleveland Cavaliers. The company has raised more than $18 million to date from institutional investors, family offices, and more than 50 physician champions. This system has helped propel the arthroscopic market to an expected US $16.3

Food and Drug Administration 52

Food and Drug Administration Medicine Recruitment Physicians 52

Pharmaceutical Technology

JANUARY 10, 2023

The erosion of Januvia is due to patent expiry in that had been expected in 2022 and physicians’ preference for sodium-glucose linked transporter-2 inhibitor (SGLT-2I) therapies such as Farxiga (dapagliflozin) and Jardiance (empagliflozin) due to their ability to improve glycemic control and address cardiorenal comorbidities.

Marketing 52

Marketing Physicians Leads Sales 52

PM360

JUNE 29, 2022

By 2025, sales of consumer health products are expected to reach $368bn, according to Euromonitor, encompassing everything from sleep aids to vitamins to sports nutrition products. markets by 2025 and 1,000 by 2027—and more than half of those practices are expected to be in medically underserved communities.

Retail 97

Retail Marketing Healthcare Healthcare 97